/images/ppid_59c68470-image-177028263189538615.webp)
/images/ppid_59c68470-image-177028016239683531.webp)
/images/ppid_59c68470-image-177028009662554031.webp)
What is the story about?
Alembic Pharmaceuticals reported a steady operating performance in Q3, with revenue rising 10.8% year-on-year to ₹1,876.3 crore, supported by consistent execution across domestic and international businesses. EBITDA grew 12.8% to ₹293.5 crore, while margins improved marginally to 15.6% from 15.4% a year ago.
Net profit declined 4.1% year-on-year to ₹132 crore, impacted by a one-time provision of ₹42 crore towards employee benefits following changes under the new labour code.
Post the earnings announcement, shares of Alembic Pharmaceuticals Ltd were trading 1.79% higher at ₹812.65 on the NSE.
India and international businesses deliver growth
The India branded business posted 6% year-on-year growth to ₹652 crore, led by the gynaecology, ophthalmology and animal healthcare segments. The anti-infective portfolio grew broadly in line with market trends, while the company also introduced four new products during the quarter.
Internationally, US generics revenue rose 6% to ₹553 crore, with two new product launches during the quarter. Ex-US international generics saw strong momentum, growing 36% year-on-year to ₹406 crore. Alembic received seven ANDA approvals during the quarter, taking cumulative approvals to 232.
Also Read: Nava Q3 Results: Revenue up 18% YoY; profit slips on manufacturing costs and tax hit
R&D focus and pipeline expansion
The API business grew 2% year-on-year to ₹264 crore. Managing Director Pranav Amin said the company maintained its operating rhythm, invested around 9% of revenue in R&D, and made progress on integrating Utility Therapeutics, with the launch of Pivya™ expected in Q4 to strengthen its US branded portfolio.
Net profit declined 4.1% year-on-year to ₹132 crore, impacted by a one-time provision of ₹42 crore towards employee benefits following changes under the new labour code.
Post the earnings announcement, shares of Alembic Pharmaceuticals Ltd were trading 1.79% higher at ₹812.65 on the NSE.
India and international businesses deliver growth
The India branded business posted 6% year-on-year growth to ₹652 crore, led by the gynaecology, ophthalmology and animal healthcare segments. The anti-infective portfolio grew broadly in line with market trends, while the company also introduced four new products during the quarter.
Internationally, US generics revenue rose 6% to ₹553 crore, with two new product launches during the quarter. Ex-US international generics saw strong momentum, growing 36% year-on-year to ₹406 crore. Alembic received seven ANDA approvals during the quarter, taking cumulative approvals to 232.
Also Read: Nava Q3 Results: Revenue up 18% YoY; profit slips on manufacturing costs and tax hit
R&D focus and pipeline expansion
The API business grew 2% year-on-year to ₹264 crore. Managing Director Pranav Amin said the company maintained its operating rhythm, invested around 9% of revenue in R&D, and made progress on integrating Utility Therapeutics, with the launch of Pivya™ expected in Q4 to strengthen its US branded portfolio.
/images/ppid_a911dc6a-image-177028182930068197.webp)
/images/ppid_a911dc6a-image-177028186664079790.webp)
